Sarepta Posts US$328.7M Results

1. Cori Fisher wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee. 
2. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
3. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

Life sciences investors are watching Sarepta after a major management change and the release of its second-quarter 2026 financial results.

Key Takeaways

• Sarepta reported US$328.7 million in Q2 2026 product revenue, led by PMO and ELEVIDYS sales.
• Sarepta posted US$13.3 million in GAAP operating income and $86.5 million in non-GAAP operating income.
• New CEO Michael Severino joined Sarepta as the company advances its rare disease pipeline.
• Phase 1/2 studies in DM1 and FSHD remain on track for data readouts in the second half of 2026.
• Sarepta's Huntington's disease program has begun dosing in its Phase 1 INSIGHTT study.
• Sarepta narrowed its 2026 revenue guidance to US$1.2 billion to US$1.3 billion and ended Q2 with approximately US$945 million in cash, cash equivalents, restricted cash and investments.

New CEO, Narrowed Revenue Guidance

After appointing a new CEO, Sarepta Therapeutics Inc. (SRPT:NASDAQ) announced its Q2 2026 financial results on August 5, 2026, with $US328.7 million in net product revenue and operating income on both a GAAP and non-GAAP basis.

Net product revenue consisted of US$230.6 million from Sarepta's phosphorodiamidate morpholino oligomer (PMO) therapies and US$98.1 million from ELEVIDYS, the company's gene therapy for Duchenne Muscular Dystrophy (DMD). Total revenue was US$401.3 million for the quarter, compared with US$611.1 million in Q2 of 2025. Sarepta attributed the decrease to lower ELEVIDYS sales after an updated label limiting treatment to the ambulatory patient population, as well as the absence of a US$63.5 million Roche milestone payment that was included in 2025's results.

However, the company reported that the decline in revenue was partially offset by higher contract manufacturing revenue related to ELEVIDYS supply delivered to Roche and US$10 million in license revenue.

Sarepta reported GAAP operating income of US$13.3 million for Q2 2026, compared with US$115.6 million in Q2 2025. Non-GAAP operating income was US$86.5 million, compared with US$162.8 million a year earlier.

Research and development expenses declined to US$91.3 million in Q2 2026 from US$204.4 million in Q2 2025. Sarepta attributed the decrease to lower manufacturing and clinical expenses following a reprioritization of its development programs, as well as lower personnel and stock-based compensation expenses following its 2025 restructuring.

Sarepta also recorded a US$39 million litigation contingency charge related to the potential resolution of certain patent litigation. The company said the potential settlement remains subject to further negotiations and will release definitive information once the settlement is completed.

On the management side, Sarepta appointed Michael Severino, MD, as CEO and a member of its board effective July 28, 2026. Severino previously held senior leadership positions at AbbVie Inc. (ABBV:NYSE), Amgen Inc. (AMGN:NASDAQ), and Merck & Co. Inc. (MRK:NYSE). Former CEO Doug Ingram retired and is expected to remain with the company in an advisory role through the end of 2026.

Severino said in the release: "As I begin my tenure as CEO, I am excited by the strength of Sarepta's foundation, the impact our therapies are having for patients, and the significant opportunities ahead. Our second quarter results, including US$328.7 million in total net product revenue and both GAAP and non-GAAP operating profitability, reflect the strength and resilience of our business. With important data readouts expected in DM1 and FSHD, continued progress across our broader pipeline, and a talented team dedicated to transforming the lives of patients with rare diseases, we have significant opportunities ahead and remain committed to delivering sustainable long-term value. Our priorities are clear: execute our commercial strategy, advance our promising siRNA pipeline, and continue allocating capital with discipline. With a strong balance sheet, an innovative pipeline, and an experienced leadership team, I believe Sarepta is well-positioned to deliver on its long-term potential."

In an operational update, Sarepta reported that readouts from the multiple-ascending-dose cohorts of its ongoing Phase 1/2 studies in DM1 and FSHD remain on track for the second half of 2026. For ELEVIDYS, Sarepta said that the company expects full enrollment of ENDEAVOR Cohort 8 by the end of 2026, with 12-week data from the full cohort expected in the first quarter of 2027.

Finally, the company has also begun dosing in INSIGHTT, its first-in-human Phase 1 study of SRP-1005, an investigational small-interfering RNA (siRNA) therapy for Huntington's disease.

The U.S. Food and Drug Administration has accepted supplemental New Drug Applications for AMONDYS 45 and VYONDYS 53, seeking conversion of their accelerated approvals to traditional approvals. The applications are supported by data from the ESSENCE confirmatory study and published real-world evidence, according to the company.

Sarepta Therapeutics Inc. is a worldwide biotech company that focuses on genetic medicine for rare diseases and is headquartered in Massachusetts, USA. The company currently has four FDA-approved therapies for treating Duchenne muscular dystrophy (DMD) and several additional programs in its pipeline.

DMD Market Growing Fast

The Duchenne Muscular Dystrophy (DMD) market was worth US$16.38 billion in 2025 and is expected to grow to US$62.13 billion by 2030, with a massive expected CAGR of 30.5%. North America was the largest regional market for DMD therapeutics in 2025.

In February 2026, IQVIA discussed the global pharma market projection for 2026, projecting that global medicine usage will approach four trillion defined daily doses by 2030. They wrote, "The largest drivers of medicine spending growth through the next five years will continue to be the use in developed markets of innovative therapeutics, especially in oncology, immunology, diabetes, and obesity."

Biopharma funding fell 20% between 2024 and 2025, according to an IQVIA analysis reported in a March 26, 2026, article for Fierce Biotech by Nick Paul Taylor. He wrote that pharma funding had fallen from 2024 but noted that, "2025 was still the third-best year of the past decade. Similarly, overall funding was well above the pre-pandemic norm and only topped by 2020, 2021, and 2024."

BCG talked about trends biopharma companies need to be aware of in 2026 in order to stay competitive, saying, "Near term, companies need to continue to innovate to decrease the complexity and cost of these therapies, and governments can find ways to incentivize and pay for them. The longer-term challenge for companies is to factor operational and economic considerations into R&D decision making earlier, ensuring that trial designs match real-world usage, indication sequences match opportunity, and endpoints enable market access."

Is the Stock a Hold?

According to TipRanks, analysts have given Sarepta the following ratings:

On August 10, 2026, Gavin Clark-Gartner of Evercore gave the company a Hold rating and a price target of US$19.

On August 7, 2026, Eliana Merle of Barclays gave the company a Hold rating and a price target of US$20.

On August 6, 2026, Ritu Baral of TD Cowen gave the company a Hold rating and a target price of US$17, Gil Blum of Needham gave the company a Sell rating, with no target price, Mitchell Kapoor of H.C. Wainwright gave the company a Sell rating, with a US$5 target price, Biren Amin of Piper Sandler gave the company a Hold rating, with a US$20 target price, Tazeen Ahmad of Bank of America gave the company a Sell rating with a US$18 target price, Michael Ulz of Morgan Stanley gave the company a Hold rating, with a US$25 target price, Kostas Biliouris of Oppenheimer gave the company a Buy rating, with a US$35 target price, Yun Zhong of Wedbush gave the company a Buy rating, with a US$35 target price, and Yanan Zhu of Wells Fargo gave the company a Buy rating, with a US$38 target price. 

Finally, on August 7, 2026, Ilya Zubkov of Freedom Broker reiterated a "Buy" rating for the company, as well as a US$25 price target, writing: "The PMO portfolio remains the most resilient part of Sarepta’s commercial business, and the quarter came in meaningfully better than our expectations . . . The long-term investment case depends on restoring ELEVIDYS' commercial trajectory and successfully advancing the siRNA pipeline as competition within PMOs increases."

Huntington's Program Begins Phase 1 Dosing

According to Sarepta's investor presentation, readouts from the multiple ascending dose (MAD) cohorts of its Phase 1/2 studies remain on track for the second half of 2026 for both SRP-1001, in facioscapulohumeral muscular dystrophy (FSHD), and SRP-1003, in myotonic dystrophy type 1 (DM1).

Ownership & Share Information¹

Sarepta Therapeutics Inc. has a market cap of US$1.91 billion, with 105.63 million shares outstanding. The company's 52-week range is US$14.68-US$25.32. Institutions own 54% of shares, while Management & Insiders own 5%. The remaining 41% of shares are Retail.

Frequently Asked Questions

Q: What is gene therapy?
A: Gene therapy is a treatment approach that uses genetic material to modify or replace faulty genes or affect how cells produce proteins.

Q: What is Duchenne muscular dystrophy (DMD)?
A: Duchenne muscular dystrophy is a genetic disorder that causes progressive muscle weakness and is most commonly diagnosed in boys.

Q: What is an siRNA therapy?
A: Small interfering RNA (siRNA) therapy uses RNA molecules to reduce the production of specific proteins by targeting messenger RNA.

Q: What is a PDUFA date?
A: A PDUFA date is the FDA's target date for completing its review of a new drug application or supplemental application under the Prescription Drug User Fee Act.